• Specialty
  • Cardiology
  • Dentistry
  • Dermatology
  • General Medicine
  • GI/GU
  • Hematology
  • Immunology
  • Lab Medicine & Pathology
  • Neuro-Psych
  • OB-Gyn
  • Oncology
  • Ophthalmology
  • Orthopaedic
  • Otolaryngology - ENT
  • Radiology
  • Surgery

• Oncology
  • Lots of Radiology/Oncology Terms
  • Cancer Classification
  • Cancer Drugs
  • Cancer Terms
  • Chemotherapy Treatments
  • Sample Reports - Hematology - Oncology

• Cancer Drugs

- X -

• xaliproden hydrochloride

The hydrochloride salt of xaliproden, an orally-active, synthetic, non-peptidic 5-HT1A receptor agonist with neurotrophic and neuroprotective properties. Although the mechanism of action of xaliproden is not fully understood, it appears to either mimic the effects of neurotrophins or stimulate their synthesis, thereby stimulating neuronal cell differentiation and proliferation and inhibiting neuronal cell death. Xaliproden\'e2\'80\'99s neuroprotective effect involves the activation of MAP kinase pathways via stimulation of the 5-HT1A receptor.



• Xanthotoxin

(Other name for: methoxsalen)



• Xcytrin

(Other name for: motexafin gadolinium)



• Xeloda

(Other name for: capecitabine)



• Xerecept

(Other name for: synthetic human corticotropin-releasing factor)



• Xinlay

(Other name for: atrasentan hydrochloride)



• XK469R

The racemic form of a synthetic quinoxaline phenoxypropionic acid derivative with antineoplastic properties. XK469R selectively inhibits topoisomerase II by stabilizing the enzyme-DNA intermediates in which topoisomerase subunits are covalently linked to DNA through 5-phosphotyrosyl linkages, thereby interfering with DNA repair and replication, RNA and protein synthesis. This agent possesses unusual solid tumor selectivity and activity against multidrug-resistant cancer cells. XK469R is more water soluble and active than the pure isomers, R(+)XK469 and S(-)XK469.



• XL184

An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. XL184 strongly binds to and inhibits several tyrosine receptor kinases. Specifically, XL184 appears to have a strong affinity for the hepatocyte growth factor receptor (Met) and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in inhibition of tumor growth and angiogenesis, and tumor regression. This agent has also been shown to inhibit mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (Flt3) and tyrosine-protein kinase receptor (Tie-2).



• XL820

An orally available, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. XL820 simultaneously inhibits the RTKs VEGF, KIT and PDGF. In tumor models of breast carcinomas, gliomas and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression.



• XL844

A synthetic small-molecule inhibitor of checkpoint kinases 1 and 2 (Chk1 and Chk2) with potential antineoplastic activity. XL844 binds to and inhibits Chks 1 and 2, resulting in inhibition of cell cycle arrest, progressive DNA damage, inhibition of DNA repair, and, ultimately, tumor cell apoptosis. This agent also inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3), important mediators of tumor angiogenesis and lymphogenesis, respectively. In the presence of DNA damage or incomplete DNA replication, eukaryotic cells activate cell cycle checkpoints that temporarily halt the cell cycle to permit DNA repair or completion of DNA replication to take place. In the presence of extensive damage or absence of timely repair, these checkpoint-signaling pathways may also trigger a pathway that effects apoptosis. Normal functions of Chks involve the initiation of cell-cycle arrest and the up-regulation of transcription genes involved with DNA excision repair and dNTP synthesis.



• XRP9881

A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic properties. XRP9881 binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. XRP9881 penetrates the blood brain barrier.



• Xylocitin

(Other name for: lidocaine)



• Xyotax

(Other name for: paclitaxel poliglumex)